Trial Profile
A Double-blind, Placebo-controlled, Randomized, Phase 1, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Mar 2018
Price :
$35
*
At a glance
- Drugs Bersacapavir (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 10 Mar 2017 Status changed to completed.
- 18 Oct 2016 New trial record